- Home
- ZYME vs GDRX Comparison
ZYME vs GDRX Comparison
Compare ZYME & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- GDRX
- Stock Information
- Founded
- ZYME 2003
- GDRX 2011
- Country
- ZYME United States
- GDRX United States
- Employees
- ZYME N/A
- GDRX N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- GDRX Retail: Computer Software & Peripheral Equipment
- Sector
- ZYME Health Care
- GDRX Technology
- Exchange
- ZYME Nasdaq
- GDRX Nasdaq
- Market Cap
- ZYME 1.2B
- GDRX 1.4B
- IPO Year
- ZYME 2017
- GDRX 2020
- Fundamental
- Price
- ZYME $16.56
- GDRX $4.39
- Analyst Decision
- ZYME Buy
- GDRX Buy
- Analyst Count
- ZYME 7
- GDRX 8
- Target Price
- ZYME $20.00
- GDRX $5.88
- AVG Volume (30 Days)
- ZYME 648.0K
- GDRX 3.7M
- Earning Date
- ZYME 10-30-2025
- GDRX 11-06-2025
- Dividend Yield
- ZYME N/A
- GDRX N/A
- EPS Growth
- ZYME N/A
- GDRX N/A
- EPS
- ZYME N/A
- GDRX 0.09
- Revenue
- ZYME $122,867,000.00
- GDRX $799,874,000.00
- Revenue This Year
- ZYME $107.76
- GDRX $2.82
- Revenue Next Year
- ZYME $2.35
- GDRX $5.31
- P/E Ratio
- ZYME N/A
- GDRX $49.16
- Revenue Growth
- ZYME 95.94
- GDRX 3.20
- 52 Week Low
- ZYME $9.03
- GDRX $3.31
- 52 Week High
- ZYME $17.70
- GDRX $7.21
- Technical
- Relative Strength Index (RSI)
- ZYME 57.31
- GDRX 52.33
- Support Level
- ZYME $16.75
- GDRX $3.85
- Resistance Level
- ZYME $17.40
- GDRX $5.39
- Average True Range (ATR)
- ZYME 0.58
- GDRX 0.30
- MACD
- ZYME -0.06
- GDRX 0.05
- Stochastic Oscillator
- ZYME 38.20
- GDRX 36.04
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About GDRX GoodRx Holdings Inc.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.